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ABSTRACT
Objective: This study aimed to identify a possible 
correlation between serum levels of anti-Müllerian 
hormone (AMH) and oocyte quality, embryo developmental 
competence, and implantation potential.
Methods: 4488 oocytes obtained from 408 patients 
undergoing ICSI cycles were evaluated. Oocyte 
dimorphisms, embryo quality on days two and three, 
blastocyst formation competence, fertilization rates, 
implantation rates, and pregnancy rates were correlated 
with serum levels of AMH using Pearson’s correlation 
coefficient and regression analysis.
Results: A positive correlation was observed between 
serum levels of AMH and number of retrieved oocytes (CC: 
0.600, p<0.001), fertilization rate (CC:0.595, p=0.048), 
and number of obtained embryos (CC:0.495, p<0.001). 
AMH did not affect the quality of cleavage stage embryos 
or the chance of blastocyst formation. However, AMH levels 
affected oocyte quality (OR:0.75, CI 0.44-0.96, p<0.001), 
and implantation (CC:0,116, p=0.031) and pregnancy 
(OR:1.22, CI:1.03-1.53, p<0.001) rates.
Conclusion: Serum levels of AMH are a useful 
predictor of ovarian response to COS, oocyte quality, and 
fertilization. However, AMH levels may also compromise 
clinical outcomes; lower AMH levels did not impair embryo 
development.
Keywords: Oocyte, blastocyst, embryo implantation, 
pregnancy, COS cells, anti-Müllerian hormone
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INTRODUCTION
Anti-Müllerian hormone (AMH), also known as Müllerian 
inhibiting substance, is a peptide growth factor and a 
member of the tissue growth factor beta superfamily. In 
male fetuses, the development of the internal reproductive 
tract requires the presence of AMH to cause the involution of 
the Müllerian ducts, the anlagen of the female reproductive 
tract (Nussey & Whitehead, 2001). In females, fetal AMH is 
produced after 36 weeks of gestation by the granulosa cells 
of primary, secondary, pre-antral, and early antral follicles 
(Durlinger et al., 1999; Rajpert-De Meyts et al., 1999; 
Weenen et al. 2004), and it continues to be expressed until 
the follicles reach the antral phase and are more than 2mm 
in diameter (Messinis, 2006).
It has been suggested that AMH inhibits the initiation 
of primordial follicle growth from the ovarian reserve 
(Weenen et al., 2004; Nilsson et al., 2007). In mice, it 
decreases the sensitivity of follicles to FSH, thereby 
inhibiting FSH-induced antral follicle growth (Durlinger 
et al., 2002). Although not fully understood, AMH may play 
a role in regulating the recruitment of cohorts of antral 
follicles (reviewed in (Baerwald et al., 2012).
The anti-Müllerian hormone, barely detectable at 
birth in females, peaks after puberty (Rajpert-De Meyts 
et al., 1999). In line with this, AMH levels have shown 
greater sensitivity to ovarian aging (de Vet et al., 2002) 
and a stronger relationship with the number of early 
antral follicles (Fanchin et al., 2003). In fact, the serum 
level of AMH has been established as the most valuable 
marker of ovarian reserve, as it correlates highly with the 
baseline antral follicle count. In addition, AMH levels are a 
useful predictor of ovarian response to controlled ovarian 
stimulation (COS) (van Rooij et al., 2002; Eldar-Geva 
et al., 2005; Tremellen et al., 2005; Nakhuda et al., 2006; 
Nakhuda et al., 2007; Nardo et al., 2009).
Previous studies found that, besides ovarian 
response to COS, the serum level of AMH can be used 
as a predictor of severity of endometriosis (Shebl et 
al., 2009). Anti-Müllerian hormone measurements 
also offer relatively high specificity and sensitivity as a 
diagnostic marker for polycystic ovary syndrome (Pigny 
et al., 2006). Moreover, as AMH declines with age and 
continues to decline until it reaches a stage in which it 
becomes undetectable in serum after menopause, it has 
also been suggested that a single AMH measurement 
may be a good predictor of the onset of menopause in 
aging women.
Despite being a good marker of ovarian response, 
AMH fails to predict the outcome of pregnancy (Lie 
Fong et al., 2008; Talebian et al., 2008; Riggs et al., 
2011), since, as suggested by Loh & Maheshwari 
(2011), it cannot predict the quality of the oocyte. 
However, previously published reports have focused on 
the assessment of embryo quality (Hazout et al., 2005; 
Silberstein et al., 2006; Smeenk et al., 2007; Lie Fong 
et al., 2008; Talebian et al., 2008) rather than oocyte 
quality, considering specifically intracytoplasmic and 
extracytoplasmic oocyte defects.
In fact, the number of retrieved oocytes and the quality 
of oocytes and embryos significantly impact the outcomes 
of assisted reproductive technology (ART). It has been 
reported that, although the percentage of embryo 
transfers that leads to deliveries has steadily increased, 
in the last years, the vast majority of embryos that are 
produced in vitro fail to develop into an infant (Kovalevsky 
& Patrizio, 2005). Therefore, the goal of the present study 
was to identify a possible correlation between serum 
levels of AMH and the following: (i) oocyte quality, (ii) 




This study analyzed the correlation between serum 
levels of AMH and (i) maternal age, (ii) maternal BMI, (iii) 
FSH dose for ovarian stimulation, (iv) number of aspirated 
follicles, (v) number of retrieved oocytes, (vi) number of 
retrieved MII mature oocytes, (vii) oocyte quality, (viii) 
fertilization rate, (ix) number of obtained embryos, (x) 
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number of obtained high-quality embryos, (xi) embryo 
quality on day two, (xii) embryo quality on day three, (xiii) 
chance of blastocyst formation, (xiv) number of transferred 
embryos, (xv) implantation rate, and (xvi) pregnancy rate.
Intra and extracytoplasmic defects were recorded 
before sperm injection for purposes of oocyte quality 
assessment. In embryo quality evaluation, the embryos 
were categorized as high or low quality on days two, 
three, and five. Fertilization rate was defined based on the 
number of oocytes presenting two clearly distinct pronuclei 
18 hours after ICSI divided by the number of injected 
oocytes. Implantation rate was calculated as the number 
of gestational sacs divided by the number of embryos 
transferred per patient. Clinical pregnancy was defined by 
the presence of a gestational sac with heartbeat viewed on 
ultrasound examination 4-6 weeks after embryo transfer.
The assessment included 4488 oocytes obtained from 
408 patients undergoing ICSI cycles between January 
2011 and August 2013. Serum AMH tests were included 
as a standard measure in the IVF program. Tests were 
run prior to the start of each cycle and AMH levels were 
recorded. The oocytes were evaluated immediately before 
sperm injection, and the embryos were evaluated 16-18h 
post-ICSI and on days two, three and five of development.
Inclusion criteria were as follows: women of good 
physical and mental health, with regular menstrual cycles 
of 25-35 days, normal basal FSH and LH levels and BMI 
lower than 30kg/m2, presence of both ovaries and an intact 
uterus, undergoing the first or second ICSI cycle. Patients 
with endometriosis or gynecological/medical disorders and 
a negative result in a screening for sexually transmitted 
diseases were excluded. All cases of severe alteration in 
spermatogenesis, including frozen and surgically retrieved 
sperm, were also excluded from the study.
The implantation rate was defined as the total number of 
gestational sacs divided by the total number of transferred 
embryos. Clinical pregnancy was defined as the presence 
of a gestational sac viewed on ultrasound examination 4-6 
weeks after embryo transfer.
The patients gave written consent before joining the 
study and agreed to share the outcomes of their cycles 
for research purposes. The local review board approved 
the study.
Controlled ovarian stimulation
Controlled ovarian stimulation was achieved using a 
daily dose of recombinant FSH (Gonal-F; Serono, Geneva, 
Switzerland) starting on day three of the cycle. Pituitary 
down-regulation was performed using a GnRH antagonist 
(Cetrotide, Serono, Geneva, Switzerland), started when at 
least one follicle ≥14mm was viewed.
Follicular growth was monitored using transvaginal 
ultrasound examination starting on day four of gonadotropin 
administration. When adequate follicular growth and serum 
E2 levels were observed, recombinant hCG (Ovidrel; 
Serono, Geneva, Switzerland) was administered to trigger 
final follicular maturation. The oocytes were collected 
35 hours after hCG administration through transvaginal 
ultrasound-guided ovum pick-up.
Preparation of oocytes
The retrieved oocytes were maintained in culture 
medium (Global® for fertilisation, LifeGlobal, Connecticut, 
USA) supplemented with 10% protein supplement (LGPS, 
LifeGlobal, Connecticut, USA) and covered with paraffin 
oil (Paraffin oil P.G., LifeGlobal, Connecticut, USA) for two 
to three hours before the removal of cumulus cells. The 
surrounding cumulus cells were removed after exposure to 
a HEPES-buffered medium containing hyaluronidase (80IU/
mL, LifeGlobal, Connecticut, USA). The remaining cumulus 
cells were gently removed with a hand-drawn Pasteur 
pipette (Humagen Fertility Diagnostics, Charlottesville, 
USA).
Oocyte morphology was assessed immediately before 
sperm injection (4 hours after retrieval) using an inverted 
Nikon Diaphot microscope (Eclipse TE 300; Nikon®, Tokyo, 
Japan) with a Hoffmann modulation contrast system under 
400X magnification. The following oocyte dysmorphisms 
were recorded: intra-cytoplasmic defects such as (i) 
cytoplasm color, (ii) vacuoles in the ooplasm, (iii) aggregates 
of smooth endoplasmic reticulum clusters (ERC) in the 
ooplasm and (iv) retractile bodies; and extracytoplasmic 
defects such as (i) large perivitelline space (PVS), (ii) PVS 
granularity, (iii) zona pellucida (ZP) abnormalities, (iv) 
shape abnormalities, and (v) fragmented polar body (PB).
Oocytes releasing the first polar body were considered 
mature and were used for ICSI.
Intracytoplasmic sperm injection
Intracytoplasmic sperm injection was performed in a 
microinjection dish prepared with 4-µL droplets of buffered 
medium (Global® w/HEPES, LifeGlobal, Connecticut, 
USA) and covered with paraffin oil on the heated stage 
of an inverted microscope (37.0±0.5°C). Approximately 
16 hours after ICSI, fertilization was confirmed by the 
presence of two pronuclei and the extrusion of the second 
polar body. Embryos were maintained in a 50-µL drop of 
culture medium (Global®, LifeGlobal, Connecticut, USA) 
supplemented with 10% protein supplement and covered 
with paraffin oil in a humidified atmosphere under 6% CO2 
at 37°C for three days.
Embryo morphology evaluation
Embryo morphology was assessed 16-18h post-ICSI 
and on the mornings of days two, three and five of embryo 
development using an inverted Nikon Diaphot microscope 
(Eclipse TE 300; Nikon, Tokyo, Japan) with a Hoffmann 
modulation contrast system under 400X magnification.
Cleavage stage morphology was assessed based on 
the following parameters: number of blastomeres, percent 
fragmentation, variation in blastomere symmetry, presence 
of multinucleation, and defects in the zona pellucida and 
cytoplasm. High-quality cleavage stage embryos had to 
show the following characteristics: 4 cells on day two or 
8-10 cells on day three, <15% fragmentation, symmetric 
blastomeres, absence of multinucleation, colorless 
cytoplasm with moderate granulation and no inclusions, 
absence of perivitelline space granularity and absence of 
zona pellucida dysmorphism. Embryos lacking any of these 
characteristics were considered to be of low quality.
In blastocyst formation assessment the embryos were 
given a numerical score from 1 to 6 based on their degree 
of expansion and hatching statuses as follows: 1, an early 
blastocyst with a blastocoel that was less than half the 
volume of the embryo; 2, a blastocyst with a blastocoel 
that was greater than half the volume of the embryo; 3, 
a full blastocyst with a blastocoel that completely filled 
the embryo; 4, an expanded blastocyst; 5, a hatching 
blastocyst; and 6, a hatched blastocyst. Embryos receiving 
scores of 3 and greater were considered a full blastocyst.
Blood collection and Anti-Müllerian hormone 
analysis
When the patients visited the outpatient department, 
serum AMH levels were obtained, regardless of the 
menstrual phase, using a human AMH ELISA Kit (CUSABIO, 
Wuhan, China).
Blood samples were collected by peripheral venipuncture 
and centrifuged at 1000×g, 4oC, for 15 minutes, within 30 
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minutes of collection; the plasma portion was removed and 
assayed.
The human AMH ELISA Kits were used according to 
supplier instructions. The intra- and inter-assay coefficients 
of variation for all assays were <10 and 15%, respectively. 
Limits of detection were: 1ng/mL-75ng/mL.
Statistical analysis
Cycle and patient characteristics were expressed as 
the mean ± standard deviation for continuous variables; 
percentages were used for categorical variables.
Pearson’s correlation coefficient was used to evaluate 
the relationship between serum AMH levels and continuous 
variables. The results were expressed in the form of 
correlation coefficients (CC) and p-values.
Binary regression analysis was performed to evaluate 
the influence of AMH levels on pregnancy rates, embryo 
quality, blastocyst formation, and oocyte defects. These 
regressions were adjusted for female age, total level of 
FSH used in controlled ovarian stimulation, and the initial 
dose of FSH, as these are potentially confounding factors 
in the association between AMH level and the evaluated 
variables. The results were expressed as odds ratios (OR), 
95% confidence intervals (CI) and p-values.
Significance was assigned to events with a p-value 
<0.05. Data analysis was carried out on Minitab Statistical 
Software (version 14).
RESULTS
Patient and cycle characteristics were as follows: 
maternal age: 37.7±5.4 (20-43) years, paternal age: 
39.0±6.7 (24-65) years; body mass index (BMI): 24.4±3.9 
(14.2-37.2); total dose of FSH administered in ovarian 
stimulation: 2370.9±855.3 (1900-3450)IU; number of 
aspirated follicles: 8.0±10.5 (1-20); number of retrieved 
oocytes: 6.7±7.4 (1-25); number of retrieved mature 
oocytes: 5.9±6.2 (1-18); fertilization rate: 82.7±20.8% 
(10-100); embryos obtained: 4.5±5.5 (1-16); high-quality 
embryos obtained: 1.5±1.1 (1-5); embryos transferred: 
1.0±1.8 (1-3); implantation rate (%): 22.0±40.2 (0-100); 
and pregnancy rate: 28.9%.
The causes of infertility were as follows: male 
factor (146/408:35.8%), tubal factor (26/408:6.4%), 
unexplained infertility (29/408:7.1%), polycystic ovary 
syndrome (PCOS, 25/408:6.1%), female factor (127/408: 
31.1%), and others (55/408:13.5%).
As expected, an inverse correlation was found between 
serum AMH levels and maternal age (CC:-0.279, p<0.001). 
Significant positive correlations were identified between 
serum AMH levels and number of aspirated follicles (CC: 
0.626, p<0.001), number of retrieved oocytes (CC:0.600, 
p<0.001), number of mature oocytes (CC:0.588, p<0.001), 
fertilization rate (CC:0.595, p=0.048), number of obtained 
embryos (CC:0.495, p<0.001), number of high-quality 
embryos (CC:0.504, p<0.001), number of transferred 
embryos (CC:0.221, p<0.001), and implantation rate 
(CC:0,116, p=0.031) (Table 1).
Serum levels of AMH also impacted pregnancy rates 
(OR:1.22, CI:1.03-1.53, p<0.001, Table 2).
The FSH dose that was used for ovarian stimulation 
(CC:0.089, p=0.075) and female BMI (CC:-0.203, 
p=0.065) did not correlate with serum AMH levels.
The serum level of AMH did not impact embryo quality 
on days two or three or the chance of blastocyst formation. 
However, AMH levels affected oocyte quality (OR:0.75, 
CI:0.44-0.96, p<0.001, Table 3).
The presence of aggregates of smooth ERC (OR:0.82, 
CI:0.63-0.99, p=0.025), large PVS (OR:0.84, CI:0.76-
0.93, p<0.001), PVS granularity (OR:0.91, CI:0.79-0.96, 
p<0.001), ZP abnormalities (OR:0.85, CI:0.73-0.94, 
p<0.001), and shape abnormalities (OR:0.83, CI:0.51-
0.93, p=0.010) were affected by the serum level of AMH. 
The presence of other dysmorphisms, such as cytoplasm 
color, vacuoles in the ooplasm, retractile bodies, and 
fragmented PB was not affected by the level of AMH (Table 
3).
DISCUSSION
Oocyte quality has been regarded as a variable that 
influences the implantation of derived embryos. It has 
been previously described that when cumulus cells are 
denuded for ICSI, more than 60% of all oocytes show at 
least one abnormal morphological characteristic (Braga 
et al., 2013). Considering that both extreme forms of 
ovarian response (low and hyper-response) may be 
associated with diminished oocyte quality (van Rooij 
et al., 2003; Figueira et al., 2011; Braga et al., 2012), we 
have hypothesized that lower levels of AMH might have a 
negative effect on oocyte and embryo development. Our 
results demonstrated that neither embryo quality on the 
cleavage stage nor the chance of blastocyst formation was 
correlated with AMH levels. However, the serum level of 
AMH was positively correlated with oocyte quality.
It remains unclear whether the correlation between 
AMH and the presence of oocyte defects is due to decreased 
secretion by granulosa cells in poor quality oocytes or due 
to a possible detrimental effect of low levels of AMH on 
oocyte quality. Indeed, AMH might play an important role 
in primordial follicle selection and cyclic growing follicle 
recruitment (Carlsson et al., 2006). Moreover, AMH might 
regulate the selection of the dominant follicle through 
the inhibitory effects of AMH on the initial recruitment of 
primary follicles from the resting primordial follicle pool 
(Durlinger et al., 2001) and through the regulation of FSH 
sensitivity in the human ovary (Kevenaar et al., 2007).
Our data also support previous reports on the prognostic 
value of AMH levels on female age (Broer et al., 2009; 
Nelson et al., 2011) and ovarian response (Broer et al., 
2009). However, the inability to estimate embryo quality and 
blastocyst formation competence by AMH levels disagreed with 
the work of Silberstein et al. (2006), in which a relationship 
was reported between AMH levels and embryo morphology. 
In the mentioned study, the morphological assessment of 
cleavage stage embryos consisted of the evaluation of cell 
number, percent fragmentation, and blastomere symmetry. 
The presence of multinucleation and defects in the zona 
pellucida and cytoplasm was not evaluated. Moreover, it failed 
to define high/low-quality embryos or to adopt any form of 
embryo scoring criteria.
In our study, the serum level of AMH affected the 
presence of intra- and extracytoplasmic defects. This 
finding agreed with an elegant trial from Fanchin et al. 
(2007), in which a clinical model of monodominant follicle 
in vitro fertilization to determine whether AMH production 
by a single, preovulatory follicle, as assessed by follicular 
fluid AMH measurements, was positively related to oocyte 
and embryo development. A direct link was suggested 
between the aptitude of granulosa cells to produce AMH 
and the functional quality of the oocyte, as reflected by 
its competence to become an embryo with implantation 
potential.
Ebner et al. (2006) also demonstrated that serum levels 
of AMH were associated with oocyte quality in stimulated 
cycles. In their study, embryo quality was not estimated 
using baseline AMH levels, which was also in accordance 
with our evidence. However, the fertilization rate was not 
correlated with the level of AMH, which disagreed with the 
results of the present study.
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  Table 1. Pearson’s correlation coefficient between the serum level of Anti-Müllerian hormone and patient and cycle 
characteristics.
Serum level of 
AMH
Variable Correlation coefficient p
Maternal age -0.279 <0.001
Maternal BMI -0.203 0.065
FSH dose 0.089 0.075
Number of aspirated follicles 0.626 <0.001
Number of retrieved oocytes 0.600 <0.001
Number of retrieved MII mature oocytes 0.588 <0.001
Fertilization Rate 0.595 0.048
Number of obtained embryos 0.495 <0.001
Number of obtained high-quality embryos 0.504 <0.001
Number of transferred Embryos 0.221 <0.001
Implantation Rate 0.116 0.031
AMH: Anti-Müllerian hormone.
  Table 2. Binary regression analysis of the effect of the serum level of Anti-Müllerian hormone on embryo quality on days 
two or three, chance of blastocyst formation, and pregnancy odds
Predictor variable Response variable P OR CI: Lower CI: Upper
Serum level of AMH
Embryo quality on day two 0.846 1.01 0.97 1.03
Embryo quality on day three 0.724 0.99 0.73 2.19
Blastocyst formation 0.574 0.98 0.54 1.96
Pregnancy <0.001 1.22 1.03- 1.53
AMH: Anti-Müllerian hormone.
  Table 3. Binary regression analysis of oocyte dysmorphisms affected by the serum level of Anti-Müllerian hormone
Predictor variable Response variable p OR CI: Lower CI: Upper
Serum level of AMH
At least one oocyte defect <0.001 0.75 0.44 0.96
Cytoplasm color 0.056 0.79 0.65 1.03
Vacuoles in the ooplasm 0.465 0.97 0.91 1.09
Aggregates of smooth ERC 0.025 0.82 0.63 0.99
Retractile Bodies 0.256 0.83 0.53 1.53
Large PVS <0.001 0.84 0.76 0.93
PVS granularity <0.001 0.91 0.79 0.96
ZP abnormalities <0.001 0.85 0.73 0.94
Shape abnormalities. 0.010 0.83 0.51 0.93
Fragmented PB 0.456 0.99 0.86 1.09
AMH: Anti-Müllerian hormone, ERC: Endoplasmic reticulum cluster, PVS: perivitelline space, ZP: Zona pellucida, PB: Polar 
Body.
The process of fertilization is initiated by gamete 
fusion and can be considered to include all the events 
associated with egg activation until the time the egg is 
committed to embryonic development (Nixon et al., 
2000). The observation that the level of AMH negatively 
affected fertilization and oocyte quality suggests a possible 
relationship between granulosa cell metabolism and 
oocyte developmental competence. Previous studies have 
shown that the degree of apoptosis of mural and cumulus 
granulosa cells negatively affects the developmental 
competence of the oocyte (Nakahara et al., 1997; Zeuner 
et al., 2003). Accordingly, human (Weenen et al., 2004) 
and animal (Bézard et al., 1987; Baarends et al., 1995) 
follicular atresia prevents the expression of AMH.
In this study, it is unclear why AMH serum levels 
affected fertilization rates and oocyte quality, but not 
embryo development. It may be suggested that, although 
the level of AMH has a significant negative effect on oocyte 
quality and fertilization capacity, once fertilized, oocytes do 
not show compromised developmental competence in vitro. 
Embryo genome is known to begin express between the 
four- and eight-cell stages of human embryo development. 
At this stage, the sperm-derived genes linked to embryo 
viability have also been disrupted (Tesarík et al., 1988).
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In addition to fertilization, our results showed the 
existence of a relationship between level of AMH and 
chance of pregnancy. Loh & Maheshwari (2011) previously 
described that AMH fails to predict the odds of pregnancy. 
Nonetheless, some reported that extremely low levels of 
AMH are associated with non-pregnancy (La Marca et al., 
2011) while others described moderate to reasonable 
pregnancy rates following extremely low levels of serum 
AMH (Lamazou et al., 2011; Weghofer et al., 2011). In our 
study, the chance of pregnancy and the number of obtained 
embryos, high-quality embryos, and transferred embryos 
were positively correlated with the level of AMH. Therefore, 
it might be argued that the correlation between AMH and 
pregnancy depends on the number of obtained oocytes and 
embryos available for transfer, rather than embryo quality. 
On the other hand, AMH levels also negatively impacted 
the implantation rate, which measures the number of 
transferred embryos.
These findings raised the question as to whether the 
worse outcomes observed for patients with lower AMH 
levels correlated with lower response to COS, decreased 
oocyte quality or both.
In conclusion, our findings indicated that the serum 
level of AMH is a useful predictor of ovarian response 
to COS, oocyte quality, fertilization, and implantation. 
However, although AMH levels might compromise 
pregnancy outcomes, lower levels of AMH do not impair 
the embryo developmental competence.
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